Irisquinone exerts anti-osteosarcoma activity by regulating the PI3K/AKT signaling pathway

Ziheng Wu, Xingxing Li, Shunjie Yao, Hao Wang, Yu Wang, Yanchao Ding, Yong Hu · 2026

Read Irisquinone exerts anti-osteosarcoma activity by regulating the PI3K/AKT signaling pathway by Ziheng Wu, Xingxing Li, Shunjie Yao, Hao Wang, Yu Wang, Yanchao Ding, Yong Hu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13500659.txt.

Description

Ziheng Wu and colleagues test in 2026 a plant compound against osteosarcoma, the aggressive bone cancer of teenagers, looking for options beyond punishing chemotherapy. The compound, irisquinone, comes from the dried roots of an iris used in traditional Chinese medicine and had shown anti-tumour effects in other cancers. Computer-based target prediction pointed first at a growth signalling route called PI3K/AKT, with one protein in it flagged as the likely core target, guiding the laboratory work that followed.

Cell experiments showed the compound suppressing cancer cell growth and migration in the reported assays. Mechanistically it dampened activation of the flagged pathway and shifted the balance of two death-regulating proteins toward cell suicide, triggering programmed death in the tumour cells. A mouse graft model confirmed the anti-tumour effect and pathway control in living tissue, giving the natural product preclinical support as a candidate for drug development.

Catalog record

CREATORZiheng Wu, Xingxing Li, Shunjie Yao, Hao Wang, Yu Wang, Yanchao Ding, Yong Hu
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE54700
LICENSEhttps://creativecommons.org/licenses/by/4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/article/MED/PMC13500659

Browse the full library · About the Tower of Babel